Lilly Onswik FDA Approval: Eli Lilly’s Weekly Basal Insulin Clears FDA for Type 2 Diabetes

Lilly Onswik FDA Approval is now official. Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection indicated alongside diet and exercise to control high blood sugar in adults with type 2 diabetes mellitus. The Indianapolis-based drugmaker said Onswik is engineered to deliver steady basal insulin levels across a full seven-day period, giving patients an alternative to the daily basal insulin injections that many currently rely on to manage their condition.

With this decision, the Lilly Onswik FDA Approval extends the company’s type 2 diabetes portfolio to include a once-weekly basal insulin alongside its existing lineup of insulins, incretins, and oral and injectable medications. Lilly said Onswik is designed to reduce injections by more than 300 per year compared with a once-daily basal insulin, a figure based on comparing 52 weekly injections against 365 daily injections; the company noted this comparison is not intended to reflect differences in safety or efficacy.

Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health, said that for over a century Lilly has developed insulins that transformed diabetes care for millions of people worldwide, but delays in starting treatment and the burden of daily injections continue to shape patients’ day-to-day experience. Custer said Onswik “offers a new once-weekly basal insulin option for patients” and reflects the company’s effort to expand choice and flexibility in type 2 diabetes management.

This marks the fourth global regulatory approval for Onswik in adults with type 2 diabetes, following earlier clearances from the European Medicines Agency (EMA), Mexico’s Federal Commission for the Protection against Sanitary Risks (COFEPRIS), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). The Lilly Onswik FDA Approval places the United States among the first major markets where the once-weekly insulin will become commercially available.

Learn More

Novo Nordisk Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes, Now Available Nationwide in the US

Lilly Onswik FDA Approval Marks Fourth Global Nod for Weekly Insulin

The FDA’s decision is grounded in data from the QWINT Phase 3 clinical trial program, which evaluated the safety and efficacy of once-weekly Onswik in more than 3,400 adults with type 2 diabetes across four global registration studies. In each QWINT trial, once-weekly Onswik met its primary endpoint of non-inferior A1C reduction from baseline compared with insulin glargine U-100 or insulin degludec U-100, the two most widely used daily basal insulin comparators in the program.

Across the QWINT studies underpinning the Lilly Onswik FDA Approval, Onswik demonstrated an overall safety profile similar to the daily basal insulins it was compared against. Lilly noted that Onswik should not be used by people with type 1 diabetes because of an increased risk of severe hypoglycemia. The most common side effects reported include low blood sugar, allergic reactions, injection-site reactions, skin thickening or pitting at the injection site (lipodystrophy), itching, rash, swelling of the hands and feet, and weight gain.

The broader clinical need behind the Lilly Onswik FDA Approval is substantial: around one in eight Americans live with diabetes, most with type 2 diabetes, and globally more than 510 million people are projected to live with the disease by 2030, with an estimated 38 million requiring insulin therapy. Lilly is positioning Onswik’s weekly dosing as a way to lower one practical barrier to starting and staying on basal insulin therapy.

Inside the Lilly Onswik FDA Approval: QWINT Phase 3 Trial Data

The QWINT program began in 2022 and enrolled patients across dozens of countries. QWINT-1 (NCT05662332) was a parallel-design, open-label, treat-to-target trial that randomized 795 insulin-naive participants across the U.S., Argentina, and Mexico to receive efsitora once weekly or insulin glargine once daily for 52 weeks, using a fixed-dosage escalation schedule targeting a fasting blood glucose of 80–130 mg/dL.

QWINT-2 (NCT05362058) randomized 928 insulin-naive participants across eleven countries, including the U.S., Brazil, Canada, China, Germany, and Japan, comparing once-weekly efsitora against once-daily insulin degludec over 52 weeks, while also assessing outcomes in patients both using and not using GLP-1 receptor agonists.

Learn More

Bristol Myers Squibb ZENBEXUS Wins FDA Accelerated Approval for Multiple Myeloma

QWINT-3 (NCT05275400) enrolled 986 participants already treated with basal insulin, comparing efsitora to degludec over 78 weeks following a three-week lead-in period, with a primary objective of demonstrating non-inferior A1C reduction at week 26. QWINT-4 (NCT05462756) randomized 730 participants who were already on basal insulin plus at least two daily mealtime insulin injections, comparing weekly efsitora to daily insulin glargine over 26 weeks alongside insulin lispro. Findings from the QWINT-3 and QWINT-4 trials were published in The Lancet, while QWINT-1 and QWINT-2 data appeared in The New England Journal of Medicine.

What the Lilly Onswik FDA Approval Means for Patients and Providers

For prescribers, the Lilly Onswik FDA Approval introduces a new weekly dosing paradigm that differs meaningfully from standard daily basal insulins. The Onswik™ KwikPen® will be available in the U.S. in the coming months in two concentrations, 500 units/mL and 1,000 units/mL, with full dosing increments and maximum single-injection limits detailed in Table 2 below.

Patients inject Onswik once each week on the same day, subcutaneously into the stomach, buttocks, thigh, or back of the upper arms, rotating injection sites to avoid thickened or damaged skin. A missed dose can be taken within four days (96 hours), then patients resume their regular weekly schedule; Onswik should never be used in an insulin pump or injected into a vein or muscle.

Lilly also flagged more serious risks tied to the therapy, including hypokalemia (low blood potassium) and a heightened risk of heart failure when Onswik is combined with thiazolidinedione (TZD) diabetes pills, even in patients with no prior history of heart problems. Providers are advised to monitor patients closely for symptoms such as shortness of breath, sudden weight gain, or swelling of the ankles or feet when TZDs and Onswik are used together.

Lilly Onswik FDA Approval Timeline, Safety Profile and Availability

Beyond the clinical and dosing details, the Lilly Onswik FDA Approval fits into a broader pattern of Lilly’s cardiometabolic pipeline expansion, which already includes GLP-1 incretin therapies and other insulin products. The company said more information on Onswik is available through its dedicated product website, and full prescribing details are outlined in the FDA-approved labeling and patient information that accompany the KwikPen.

Lilly’s announcement included standard forward-looking language noting that, as with any pharmaceutical product, there is no guarantee that Onswik will receive additional regulatory approvals in remaining markets or achieve commercial success, and that future study results may not always be consistent with results to date. Investors and industry watchers tracking the Lilly Onswik FDA Approval can review the company’s full risk disclosures in its SEC filings, while clinicians can consult the QWINT trial registrations directly for study design and eligibility details.

QWINT Phase 3 Program Overview

Global Regulatory Approval Timeline for Onswik